All posts by: Michael Zand

About Michael Zand

A first-of-its-kind treatment for blindness just got one step closer to approval – Business Insider

Continue reading

2017-10-12 NEWS

Business Insider

A first-of-its-kind treatment for blindness just got one step closer to approval
Business Insider
Gene therapy hereditary blindness eye exam In this Oct. 4, 2017 photo, Dr. Albert Maguire checks the eyes of Misa Kaabali, 8, at the Children’s Hospital of Philadelphia. Misa was 4 years old when he received his gene therapy treatment. AP. A US Food

and more »

Continue reading

2017-10-12 NEWS

NPR

FDA Panel Endorses Gene Therapy For A Form Of Childhood Blindness
NPR
A Food and Drug Administration advisory committee endorsed the first gene therapy for an inherited disorder — a rare condition that causes a progressive form of blindness that usually starts in childhood. The recommendation came in a unanimous 16-0
Gene Therapy: How a New Cure for Blindness Reverses Retinal DystrophyNewsweek
The Time Has Come: 4 Gene Therapy Stocks to Buy, 1 to AvoidBarron’s
FDA Vote Sets Stage for Gene Therapy’s FutureMIT Technology Review
Bloomberg –ABC News –Futurism
all 81 news articles »
Continue reading

2017-10-12 NEWS

The San Diego Union-Tribune

HIV controlled with improved CAR T therapy; human testing planned next spring
The San Diego Union-Tribune
A breakthrough cancer treatment is to be tested in patients next year for its original purpose, controlling HIV infection. Researchers at the University of Pennsylvania, where its use in cancer was pioneered, say they’ve tweaked multiple facets of what
Reengineered immune system cells show early promise against HIVMedical Xpress
Our best chance to end cancerThe Daily Reckoning

all 3 news articles »

Continue reading

2017-10-12 NEWS

Israeli researcher: immunotherapy ‘future’ of treatment
Cleveland Jewish News
Yarden: Immunotherapy is at the very heart of my research. One clear way to void the growth factors is to use antibodies. Antibodies are molecules – we can engineer them to get rid of growth factors. Now, we can engineer the antibodies to make them